Results 21 to 30 of about 3,015 (189)

Risk Factors for Phenoconversion in Rapid Eye Movement Sleep Behavior Disorder [PDF]

Annals of Neurology, 2022
Objective: This study was undertaken to follow up predictive factors for α-synuclein–related neurodegenerative diseases in a multicenter cohort of idiopathic/isolated rapid eye movement sleep behavior disorder (iRBD).
Arnulf I., Dauvilliers Y., Fantini M. L., Ferini-Strambi L., Figorilli M., Frauscher B., Hogl B., Ibrahim A., Iranzo A., Janzen A., Ju Y. -E., Leu-Semenescu S., Manni R., Miyamoto M., Miyamoto T., Montplaisir J. Y., Oertel W. H., Pelletier A., Postuma R. B., Puligheddu M., Sonka K., Stefani A., Terzaghi M., Zhang H., Zucconi M.   +24 more
core   +5 more sources

Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion. [PDF]

PLoS ONE, 2016
Resveratrol, a phytoalexin found in berries, peanuts, grapes, and red wine, inhibits oxidation, inflammation, and cell proliferation and collagen synthesis in multiple cell types and or animal models.
Mehrnaz Gharaee-Kermani, Bethany B Moore, Jill A Macoska   +2 more
doaj   +4 more sources

Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study [PDF]

Clinical and Translational Science
Phenoconversion is the discrepancy between genotype‐predicted phenotype and clinical phenotype, due to nongenetic factors. In oncology patients, the impact of phenoconversion on drug selection, efficacy, toxicity, and treatment outcomes is unknown.
Rachel Conyers, Tayla Stenta, Andrew A. Somogyi, Carl Kirkpatrick, Andreas Halman, Sophie Wang, Claire Moore, Dhrita Khatri, Elizabeth Williams, Roxanne Dyas, Tim Spelman, David A. Elliott, Amanda Gwee, Marliese Alexander   +13 more
doaj   +2 more sources

Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients [PDF]

British Journal of Clinical Pharmacology
AbstractAimsPhenoconversion, a genotype‐phenotype mismatch, challenges a successful implementation of personalized medicine. The aim of this study was to detect and determine phenoconversion using the solanidine metabolites 3,4‐seco‐solanidine‐3,4‐dioic acid (SSDA) and 4‐OH‐solanidine as diet‐derived cytochrome P450 2D6 (CYP2D6) biomarkers in a ...
Jens Andreas Sarömba, Julian Peter Müller, Jolanta Tupiec, Anjali Roeth, Berkan Kurt, Florian Kahles, Thea Laurentius, Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
openaire   +4 more sources

Free water predicts dementia with Lewy bodies in isolated REM sleep behavior disorder [PDF]

Alzheimers Dement
INTRODUCTION: Most individuals with isolated rapid eye movement sleep behavior disorder (iRBD) develop dementia with Lewy bodies (DLB) or Parkinson's disease (PD). Brain biomarkers predicting specific phenoconversion trajectories are lacking. METHODS: In
Arnulf, Isabelle, Ayral, Violette, Boré, Arnaud, Corvol, Jean‐Christophe, Daneault, Véronique, Descoteaux, Maxime, Dusek, Petr, Filiatrault, Marie, Gagnon, Jean‐François, Group, ICEBERG Study, Haddad, Celine, Hu, Michele T., Klein, Johannes, Lehéricy, Stéphane, Marecek, Stanislav, Pastor‐Bernier, Alexandre, Postuma, Ronald B., Rahayel, Shady, Tremblay, Christina, Varga, Zsoka, Vidailhet, Marie, Vo, Andrew   +21 more
core   +3 more sources

Longitudinal network changes and phenoconversion risk in isolated REM sleep behavior disorder

Nature Communications
Isolated rapid eye movement sleep behavior disorder is a prodrome of α-synucleinopathies. Using positron emission tomography, we assessed changes in Parkinson’s disease-related motor and cognitive metabolic networks and caudate/putamen dopaminergic input
Chris C. Tang, Yoshikazu Nakano, An Vo, Nha Nguyen, Katharina A. Schindlbeck, Paul J. Mattis, Kathleen L. Poston, Jean-François Gagnon, Ronald B. Postuma, Martin Niethammer, Yilong Ma, Shichun Peng, Vijay Dhawan, David Eidelberg   +13 more
doaj   +5 more sources

Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses [PDF]

Frontiers in Pharmacology
Escitalopram is widely regarded as a well-tolerated selective serotonin reuptake inhibitor (SSRI) with a favorable safety profile. However, severe adverse events can occur even at therapeutic doses in susceptible individuals.
Zongchen Jiang, Xiaoyu Qu, Zimin Yan, Jungang Fang, Jin Lan, Xin Zhao, Wensheng Qi   +6 more
doaj   +2 more sources

Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review [PDF]

Journal of Clinical Medicine, 2020
Phenoconversion is the mismatch between the individual’s genotype-based prediction of drug metabolism and the true capacity to metabolize drugs due to nongenetic factors. While the concept of phenoconversion has been described in narrative reviews, no systematic review is available.
Sylvia D. Klomp, Martijn L. Manson, Henk-Jan Guchelaar, Jesse J. Swen   +3 more
openaire   +5 more sources

"Phenoconversion in adult patients with b-thalassemia" [PDF]

Patients with clinically significant forms of β-thalassemia have been historically classified as having a β-thalassemia major or β-thalassemia intermedia phenotype, with the first primarily referring to patients who present with severe anemia during ...
Barella S, Culcasi M, De Franceschi L, Ferrero GBm Lisi R, Forni G, Gianesin B, Long F, Musallam KM, Origa R, Pasanisi A, Pinto V, Roberti D, Sciortino R   +12 more
core   +2 more sources

Unawareness of motor phenoconversion in Huntington disease [PDF]

Neurology, 2013
To determine whether Huntington disease (HD) mutation carriers have motor symptoms (complaints) when definite motor onset (motor phenoconversion) is diagnosed and document differences between the groups with and without unawareness of motor signs.We analyzed data from 550 HD mutation carriers participating in the multicenter PREDICT-HD Study followed ...
Elizabeth A, McCusker, David G, Gunn, Eric A, Epping, Clement T, Loy, Kylie, Radford, Jane, Griffith, James A, Mills, Jeffrey D, Long, Jane S, Paulsen   +8 more
openaire   +2 more sources